Online citations, reference lists, and bibliographies.
← Back to Search

Novel Therapies For Malignant Pleural Mesothelioma.

A. Scherpereel, F. Wallyn, S. Albelda, C. Munck
Published 2018 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Malignant pleural mesothelioma is a rare cancer that is typically associated with exposure to asbestos. Patients with malignant pleural mesothelioma have poor outcomes with suboptimal therapeutic options and currently no treatment is curative. The standard frontline treatment, cisplatin plus pemetrexed chemotherapy, has only short and insufficient efficacy, and no validated treatment beyond first-line therapy is available. New therapeutic strategies are therefore needed. The addition of bevacizumab (an anti-VEGF antibody) combined with cisplatin plus pemetrexed has shown some promise. However, immunotherapy, especially immune checkpoint inhibitors, has generated a lot of excitement because of data suggesting the potential value of immune checkpoint inhibitors for patients who have failed chemotherapy. In this Review, we describe immune checkpoint inhibitors, other immunotherapies, targeted therapies, or combinations of novel drugs being investigated in malignant pleural mesothelioma, as well as the issues surrounding the selection of the best candidates for these treatments.
This paper references
10.1097/00000478-200308000-00001
The Immunohistochemical Diagnosis of Mesothelioma: A Comparative Study of Epithelioid Mesothelioma and Lung Adenocarcinoma
N. Ordóñez (2003)
10.1016/j.rmed.2010.04.026
Spontaneous regression of thoracic malignancies.
T. Kumar (2010)
10.1126/scitranslmed.3008639
Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship
I. Shapiro (2014)
10.1016/j.lungcan.2012.05.111
A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.
J. Dowell (2012)
10.1016/S1470-2045(17)30621-6
Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
N. van Zandwijk (2017)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1158/1078-0432.CCR-15-2133
Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy
D. Sterman (2016)
10.1016/S1470-2045(16)30387-4
Prophylactic radiotherapy to prevent procedure-tract metastases.
G. Zalcman (2016)
10.1183/09031936.00063109
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
10.1200/JCO.2017.35.15_SUPPL.8557
Biomarkers of pembrolizumab (P) activity in mesothelioma (MM): Results from a phase II trial.
H. Kindler (2017)
10.1097/JTO.0000000000000471
High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma
Masaki Nasu (2015)
10.3978/j.issn.2072-1439.2013.11.28
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.
N. van Zandwijk (2013)
10.1038/nrclinonc.2017.27
Drugs that lack single-agent activity: are they worth pursuing in combination?
B. Gyawali (2017)
10.1016/S1470-2045(13)70381-4
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
L. Calabrò (2013)
10.1007/s00262-010-0881-6
CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection
N. Yamada (2010)
10.1038/sj.bjc.6690105
The European mesothelioma epidemic
J. Peto (1999)
10.1016/J.JTHO.2016.11.300
OA13.01 A Phase II Study of Nivolumab in Malignant Pleural Mesothelioma (NivoMes): with Translational Research (TR) Biopies
J. Quispel-Janssen (2017)
10.1016/j.jtho.2016.01.014
A Randomized Phase II Study Adding Axitinib to Pemetrexed‐Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single‐Center Trial Combining Clinical and Translational Outcomes
W. Buikhuisen (2016)
10.1001/jamaoncol.2016.3049
Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1–Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial
P. Szlosarek (2017)
10.1038/bjc.2013.368
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
G. Ceresoli (2013)
10.1016/j.pharmthera.2014.10.001
FAK signaling in human cancer as a target for therapeutics.
Brian Y. Lee (2015)
10.1016/j.jtho.2017.05.021
Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905)
A. Tsao (2017)
10.1158/2326-6066.CIR-16-0171
Cytotoxic T Cells in PD-L1–Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors
M. Awad (2016)
10.1016/S1470-2045(16)30095-X
Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial
A. Clive (2016)
10.1158/1078-0432.CCR-17-2169
A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma
M. Zauderer (2017)
10.1200/JCO.2017.35.15_SUPPL.8555
Effect of FAK inhibitor defactinib on tumor immune changes and tumor reductions in a phase II window of opportunity study in malignant pleural mesothelioma (MPM).
R. Bueno (2017)
10.1016/j.lungcan.2011.08.011
Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
P. Zucali (2012)
10.3978/j.issn.2225-319X.2012.11.04
Malignant pleural mesothelioma: an epidemiological perspective.
Benjamin M. Robinson (2012)
10.1183/09031936.00037310
Valproate–doxorubicin: promising therapy for progressing mesothelioma. A phase II study
A. Scherpereel (2010)
10.1080/10937404.2016.1193361
Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles
P. Andujar (2016)
10.1097/JTO.0000000000000177
B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis
A. Mansfield (2014)
10.1179/2049396712Y.0000000016
Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003–2008
S. Jane Henley (2013)
10.1016/j.cell.2015.09.001
Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity
A. Serrels (2015)
10.1097/JTO.0b013e31828c2b26
Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy
S. Papa (2013)
10.1200/JCO.2017.35.18_SUPPL.LBA8507
Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial
A. Scherpereel (2017)
10.1093/annonc/mdw427
A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors.
J. Soria (2016)
10.1200/JCO.2005.04.3190
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
G. Ceresoli (2006)
10.1158/1535-7163.MCT-11-0454
Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development
R. Kelly (2012)
10.1200/JCO.2011.41.5869
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
H. Kindler (2012)
10.1200/JCO.2017.35.15_SUPPL.8514
Outcomes of anti-PD-1 therapy in mesothelioma and correlation with PD-L1 expression
G. Rivalland (2017)
10.1200/JCO.2017.72.9012
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.
F. Grosso (2017)
10.1155/2012/927240
New Roads Open Up for Implementing Immunotherapy in Mesothelioma
R. Cornelissen (2012)
10.1007/s00262-010-0871-8
WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer
L. Krug (2010)
10.1158/2326-6066.CIR-13-0170
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
G. Beatty (2013)
10.1016/S1470-2045(13)70125-6
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
W. Buikhuisen (2013)
10.1093/annonc/mdq173
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
R. Stahel (2010)
10.1016/j.cllc.2013.12.008
Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.
A. Tsao (2014)
10.1159/000339259
Malignant Pleural Mesothelioma: From the Bench to the Bedside
P. Astoul (2012)
10.1016/S1556-0864(16)30330-6
CRS‐207 with chemotherapy (chemo) in malignant pleural mesothelioma (MPM): Results from a phase 1b trial: 208O_PR
T. Jahan (2016)
10.1158/0008-5472.CAN-14-1328
Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma.
Jinfei Xu (2014)
10.1016/j.lungcan.2014.03.006
Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.
M. Zauderer (2014)
10.1038/ng.912
Germline BAP1 mutations predispose to malignant mesothelioma
J. Testa (2011)
10.1164/rccm.201508-1573OC
Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma.
R. Cornelissen (2016)
10.1016/S1470-2045(17)30446-1
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
M. Maio (2017)
10.1016/S1470-2045(15)70056-2
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.
L. Krug (2015)
10.1371/journal.pone.0121071
Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)
S. Cedrés (2015)
10.1016/j.lungcan.2015.06.018
Second line therapy in malignant pleural mesothelioma: A systematic review.
W. Buikhuisen (2015)
10.1016/S1470-2045(17)30459-X
Radiotherapy for the treatment of malignant pleural mesothelioma.
M. Perrot (2017)
10.5306/wjco.v7.i2.135
Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment.
I. Marchesi (2016)
10.1080/21678707.2017.1325358
Current and prospective pharmacotherapies for the treatment of pleural mesothelioma
Emyr Bakker (2017)
10.1172/JCI91190
IFN-&ggr;–related mRNA profile predicts clinical response to PD-1 blockade
M. Ayers (2017)
10.2471/BLT.13.132118
Asbestos: use, bans and disease burden in Europe
T. Kameda (2014)
10.1016/j.immuni.2013.07.012
Oncology meets immunology: the cancer-immunity cycle.
D. Chen (2013)
10.1038/srep31745
Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment
P. Lizotte (2016)
10.1126/scitranslmed.aak9679
Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
Elizabeth Allen (2017)
10.1016/S0140-6736(15)01238-6
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
G. Zalcman (2016)
10.1016/S1470-2045(17)30169-9
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
E. Alley (2017)
10.3389/fonc.2017.00179
Oncolytic Viral Therapy for Mesothelioma
D. Pease (2017)
10.1164/rccm.201608-1755CI
Checkpoint Blockade in Lung Cancer and Mesothelioma
L. Lievense (2017)
10.1200/JCO.2017.35.15_SUPPL.8553
Expansion study of ADI-PEG 20, pemetrexed and cisplatin in patients with ASS1-deficient malignant pleural mesothelioma (TRAP).
Melissa M. Phillips (2017)



This paper is referenced by
10.1053/j.jvca.2020.07.017
The 2019 ERS/ESTS/EACTS/ESTRO Guidelines on the Management of Patients With Malignant Pleural Mesothelioma.
T. Gelzinis (2020)
10.3390/ijms21051839
Curcumin as an Anticancer Agent in Malignant Mesothelioma: A Review
A. Baldi (2020)
10.1002/mc.23088
Association of two BRM promoter polymorphisms and smoking status with malignant pleural mesothelioma risk and prognosis
M. J. Lee (2019)
10.1080/17476348.2019.1678386
Approved and emerging treatments of malignant pleural mesothelioma in elderly patients
G. Ceresoli (2019)
10.1111/cas.14523
Tumor‐associated macrophage‐derived inflammatory cytokine enhances malignant potential of malignant pleural mesothelioma
D. Horio (2020)
10.7759/cureus.2749
Malignant Pleural Mesothelioma, Biphasic Type: An Unusual and Insidious Case of Rapidly Progressive Small Blue Cell Tumor
C. Salazar (2018)
10.3390/cancers12051186
Malignant Pleural Mesothelioma: Genetic and Microenviromental Heterogeneity as an Unexpected Reading Frame and Therapeutic Challenge
D. M. Abbott (2020)
10.1016/j.cllc.2020.06.028
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study.
D. Cortinovis (2020)
10.1159/000507373
Mutational Profiling of Driver Tumor Suppressor and Oncogenic Genes in Brazilian Malignant Pleural Mesotheliomas
N. Campanella (2020)
10.1016/s1470-2045(19)30532-7
Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
G. Ceresoli (2019)
10.1016/S1470-2045(18)30765-4
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
A. Scherpereel (2019)
10.1007/s11864-019-0613-x
Use of Immune Checkpoint Inhibitors in Mesothelioma
P. Forde (2019)
Pleura and Peritoneum
Naoual Bakrin (2018)
10.3390/cancers12061484
TGFα Promotes Chemoresistance of Malignant Pleural Mesothelioma
B. Staumont (2020)
10.1016/j.jtocrr.2020.100075
Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian Population
Tamkin Ahmadzada (2020)
10.1016/j.canlet.2019.03.001
Card9 as a critical regulator of tumor development.
X. Zhong (2019)
10.1016/j.jtho.2018.06.011
Scientific Advances and New Frontiers in Mesothelioma Therapeutics.
L. Mutti (2018)
10.3390/cancers11121839
Targeting Calcium Signalling in Malignant Mesothelioma †
S. Martinotti (2019)
10.1016/j.canlet.2019.12.016
Cisplatin unleashes Toll-like receptor 3-mediated apoptosis through the downregulation of c-FLIP in malignant mesothelioma.
Béatrice Vanbervliet-Defrance (2019)
10.1053/j.seminoncol.2019.06.001
Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.
A. Tsao (2019)
10.1183/13993003.00953-2019
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
A. Scherpereel (2020)
10.1136/jitc-2020-000713
Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab
A. Minchom (2020)
10.3389/fphar.2018.01129
Metabolic Characterization of Antifolate Responsiveness and Non-responsiveness in Malignant Pleural Mesothelioma Cells
Y. Sato (2018)
10.1038/s41467-019-09307-6
Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications
Y. Blum (2019)
10.1007/978-3-030-16884-1_16
Targeting Angiogenesis in Malignant Pleural Mesothelioma
A. Scherpereel (2019)
10.1080/23723556.2019.1610322
Unraveling the cellular heterogeneity of malignant pleural mesothelioma through a deconvolution approach
Y. Blum (2019)
10.1111/pin.13028
Expression status of PD-L1 and B7-H3 in mesothelioma.
E. Matsumura (2020)
10.3389/fonc.2020.579464
Therapeutic Landscape of Malignant Pleural Mesothelioma: Collateral Vulnerabilities and Evolutionary Dependencies in the Spotlight
Duo Xu (2020)
10.32388/mc7x5b
Molecular Carcinogenesis
Y. Zhu (2019)
10.1515/pp-2019-0010
MESOTIP: Phase II multicenter randomized trial evaluating the association of PIPAC and systemic chemotherapy vs. systemic chemotherapy alone as 1st-line treatment of malignant peritoneal mesothelioma
O. Sgarbura (2019)
10.1016/j.rmed.2018.06.026
A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma.
F. Petrelli (2018)
10.3390/ijms21176342
Genomics and Functional Genomics of Malignant Pleural Mesothelioma
Ece Çakıroğlu (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar